No Data
Arcutis Biotherapeutics to Present New Data on ZORYVE for Atopic Dermatitis and Psoriasis at 2025 AAD Annual Meeting
Arcutis To Present At 83rd American Academy Of Dermatology Annual Meeting
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Arcutis Biotherapeutics Shines in Earnings Call
Goldman Sachs Maintains Arcutis Biotherapeutics(ARQT.US) With Hold Rating, Raises Target Price to $15
Arcutis Biotherapeutics Is Maintained at Outperform by Mizuho
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}